eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Abbott Healthcare Products Limited

Solvay Healthcare, Mansbridge Road, West End, Southampton, SO18 3JD
Telephone: +44 (0)2380 467 000
Fax: +44 (0)2380 465 350
Medical Information e-mail: medinfo.shl@abbott.com
Customer Care direct line: +44 (0)1753 650 099
Medical Information Fax: +44 (0)2380 465 350

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 15/11/2011
SPC Klaricid 500mg tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 15/11/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic Properties
Updated on 17/02/2011 and displayed until 15/11/2011
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
Updated on 08/01/2010 and displayed until 17/02/2011
Reasons for adding or updating:
  • Change to section 10 date of revision of the text
  • Change to section 7 - Marketing Authorisation Holder
Updated on 26/09/2006 and displayed until 08/01/2010
Reasons for adding or updating:
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6. 6 - Instruction for Use/Handling
Updated on 26/09/2006 and displayed until 26/09/2006
Reasons for adding or updating:
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6. 6 - Instruction for Use/Handling
Updated on 20/09/2006 and displayed until 26/09/2006
Reasons for adding or updating:
  • Correction of spelling/typing errors
  • Pending awaiting re-submission
Updated on 19/09/2006 and displayed until 20/09/2006
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
Updated on 11/10/2005 and displayed until 19/09/2006
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 (date of (partial) revision of the text
Updated on 12/08/2005 and displayed until 11/10/2005
Reasons for adding or updating:
  • Change to section 10 (date of (partial) revision of the text
Updated on 24/08/2001 and displayed until 12/08/2005
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
Updated on 06/09/1999 and displayed until 24/08/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   clarithromycin